IP Library Granted Patent US 8,165,651
Granted Patent B2
US 8,165,651 · App. 11/007,617 · Granted Apr 24, 2012

Analyte sensor, and associated system and method employing a catalytic agent

Assignee: Abbott Diabetes Care Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,165,651
App. No.
11/007,617
Granted
Apr 24, 2012
Kind
B2
Abstract

An analyte sensor for use in connection with a biofluid is described. The analyte sensor may comprise any suitable interface between the biofluid and a derivative of the biofluid and any suitable transducer of information concerning an analyte. At least one catalytic agent is provided in a locale or vicinity of the interface. The catalytic agent, such as a proteinaceous agent or a non-proteinaceous, organic-metal agent, is sufficient to catalyze the degradation of reactive oxygen and/or nitrogen species that may be present in the vicinity of the interface. An analyte-sensing kit and a method of sensing an analyte are also described.

Claims (31)

1. An analyte sensor for use in connection with a biofluid, comprising:

a transducer sufficient for generating a signal that corresponds to a concentration of an analyte in a derivative portion of the biofluid when the derivative portion of the biofluid contacts the transducer, wherein the transducer comprises an analyte responsive enzyme and wherein the analyte responsive enzyme oxidizes the analyte;

an interface sufficient for passage of the derivative portion of the biofluid toward the transducer when the biofluid contacts the interface; and

an organic-metal catalytic agent disposed only in the interface and sufficient to catalyze the degradation of reactive oxygen species and/or reactive nitrogen species of biological origin in the biofluid and/or the derivative portion of the biofluid, the agent selected from a proteinaceous catalytic agent, a non-proteinaceous catalytic agent, or any combination thereof.

2. The sensor of claim 1 , wherein the sensor is partially implantable in a body.

3. The sensor of claim 1 , wherein the sensor is a transcutaneous sensor.

4. The sensor of claim 1 , wherein the sensor is fully implantable in a body.

5. The sensor of claim 1 , wherein the transducer is an electrochemical transducer.

6. The sensor of claim 1 , wherein the interface comprises a membrane that at least partially covers the transducer.

7. The sensor of claim 1 , wherein the metal of the organic-metal catalytic agent is manganese.

8. The sensor of claim 1 , wherein the catalytic agent is MnTPyP.

9. The sensor of claim 1 , wherein the catalytic agent is associated with an outer surface of the sensor.

10. The sensor of claim 1 , wherein the catalytic agent is an agent of sensor biocompatibility.

11. The sensor of claim 1 , wherein the catalytic agent is an agent of sensor signal quality.

12. The sensor of claim 1 , wherein the catalytic agent is an anti-neutrophilic agent.

13. The sensor of claim 1 , wherein the analyte responsive enzyme is glucose oxidase.

14. An analyte sensor for use in connection with a biofluid, comprising:

a transducer sufficient for generating a signal that corresponds to a concentration of an analyte in a derivative portion of the biofluid when the derivative portion of the biofluid contacts the transducer, wherein the transducer comprises an analyte responsive enzyme and wherein the analyte responsive enzyme oxidizes the analyte;

an interface sufficient for passage of the derivative portion of the biofluid toward the transducer when the biofluid contacts the interface; and

an organic-metal catalytic agent disposed only in the interface, the agent selected from a proteinaceous catalytic agent, a non-proteinaceous, organic-metal catalytic agent, or any combination thereof, the agent sufficient to mitigate the recruitment of neutrophils to the locale.

15. The sensor of claim 14 , wherein the analyte responsive enzyme is glucose oxidase.

16. The sensor of claim 14 , wherein the sensor is partially implantable in a body.

17. The sensor of claim 14 , wherein the sensor is a transcutaneous sensor.

18. The sensor of claim 14 , wherein the sensor is fully implantable in a body.

19. The sensor of claim 14 , wherein the transducer is an electrochemical transducer.

20. The sensor of claim 14 , wherein the interface comprises a membrane that at least partially covers the transducer.

21. The sensor of claim 14 , wherein the metal of the organic-metal catalytic agent is manganese.

22. The sensor of claim 14 , wherein the catalytic agent is MnTPyP.

23. The sensor of claim 14 , wherein the catalytic agent is associated with an outer surface of the sensor.

24. The sensor of claim 14 , wherein the catalytic agent is an agent of sensor biocompatibility.

25. The sensor of claim 14 , wherein the catalytic agent is an agent of sensor signal quality.

Assignments (2)
CHANGE OF NAME Recorded Feb 7, 2008
From: THERASENSE, INC.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 020480/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2005
From: FELDMAN, BENJAMIN J.; LIU, ZENGHE; COHEN, DAVID C.; HELLER, ADAM
To: THERASENSE, INC.
Reel/Frame 016332/0333 →
Continuity (3)
Continuation In Part 10819498 · Apr 6, 2004
Continuation In Part 10775604 · Feb 9, 2004
Related Publication 20050215871A1 · Sep 29, 2005